Oral and Parenteral Therapeutic Options for Outpatient Urinary Infections Caused byEnterobacteriaceaeProducing CTX-M Extended-Spectrum β-Lactamases

Oral and Parenteral Therapeutic Options for Outpatient Urinary Infections Caused byEnterobacteriaceaeProducing CTX-M Extended-Spectrum β-Lactamases Oral Treatment Options for Ambulatory Patients with Urinary Tract Infections Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli Surveillance of Community-Based Reservoirs Reveals the Presence of CTX-M, Imported AmpC, and OXA-30 β-Lactamases in Urine Isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. Community Prevalence of Fosfomycin Resistance among CTX-M-Producing Escherichia coli Clinical Isolates in Japan and Identification of Novel Plasmid-Mediated Fosfomycin-Modifying Enzymes Urine Bactericidal Activity against Escherichia coli Isolates Exhibiting Different Resistance Phenotypes/Genotypes in an In Vitro Pharmacodynamic Model Simulating Urine Concentrations Obtained after Oral Administration of a 400-Milligram Single Dose of Cefditoren-Pivoxil Extended-Spectrum β-Lactamases of the CTX-M Type Now in Switzerland Identification and Characterization of CTX-M-Producing Shigella Isolates in the United States Spread of Extended-Spectrum β-Lactamase CTX-M-Producing Escherichia coli Clinical Isolates in Community and Nosocomial Environments in Portugal Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Strains in Various Types of Private Health Care Centers Comparison of the Efficacies of Oral β-Lactams in Selection of Haemophilus influenzae Transformants with Mutated ftsI Genes